# Exemestane in Advanced and Recurrent Endometrial Carcinoma

> **NCT01965080** · PHASE2 · COMPLETED · sponsor: **Nordic Society of Gynaecological Oncology - Clinical Trials Unit** · enrollment: 52 (actual)

## Conditions studied

- Endometrial Cancer

## Interventions

- **DRUG:** Exemestane

## Key facts

- **NCT ID:** NCT01965080
- **Lead sponsor:** Nordic Society of Gynaecological Oncology - Clinical Trials Unit
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-03
- **Primary completion:** 2009-02
- **Final completion:** 2009-02
- **Target enrollment:** 52 (ACTUAL)
- **Last updated:** 2013-10-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01965080

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01965080, "Exemestane in Advanced and Recurrent Endometrial Carcinoma". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT01965080. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*